

DAFTAR PUSTAKA

- Ahn, S. M., Byun, K., Cho, K., Kim, J. Y., Yoo, J. S., Kim, D., Paek, S. H., Kim, S. U., Simpson, R. J. and Lee, B. (2008) 'Human microglial cells synthesize albumin in brain', *PLoS ONE*, 3(7), pp. 4–9. doi: 10.1371/journal.pone.0002829.
- Asbury, A. K. and Cornblath, D. R. (1990) 'Assessment of current diagnostic criteria for Guillain - Barré syndrome' , *Annals of Neurology*, 27(1 S), pp. S21-S24. doi: 10.1002/ana.410270707.
- Badshah, M., Ahmed, D., Barre, G. and Gbs, S. (2018) 'Association of serum albumin levels and guillain barre syndrome (gbs) outcome .', *Pakistan Journal of Neurological Sciences*, 13(2), pp. 1–6.
- Bae, J. C., Seo, S. H., Hur, K. Y., Kim, J. H., Lee, M.-S., Lee, M. K., Lee, W. Y., Rhee, E. J. and Oh, K. W. (2013) 'Association between Serum Albumin, Insulin Resistance, and Incident Diabetes in Nondiabetic Subjects', *Endocrinology and Metabolism*, 28(1), p. 26. doi: 10.3803/enm.2013.28.1.26.
- Brenner, D. A., Buck, M., Feitelberg, S. P. and Chojkier, M. (1990) 'Tumor necrosis factor- α inhibits albumin gene expression in a murine model of cachexia', *Journal of Clinical Investigation*, 85(1), pp. 248–255. doi: 10.1172/JCI114419.
- Brettell, R. P., Gross, M., Legg, N. J., Lockwood, M. and Pallis, C. (1978) 'Treatment of Acute Polyneuropathy By Plasma Exchange', *The Lancet*, 312(8099), p. 1100. doi: 10.1016/S0140-6736(78)91837-8.
- Caraceni, P., Tufoni, M. and Bonavita, M. E. (2013) 'Clinical use of albumin' , *Blood Transfusion*, 11(SUPPL. 4). doi: 10.2450/2013.005s.
- Castell, J. V., Gómez - lechón, M. J., David, M., Fabra, R., Trullenque, R. and Heinrich, P. C. (1990) 'Acute - phase response of human hepatocytes: Regulation of acute - phase protein synthesis by interleukin - 6' , *Hepatology*, 12(5), pp. 1179-1186. doi: 10.1002/hep.1840120517.

- Chen, Q., Lu, M., Monks, B. R. and Birnbaum, M. J. (2016) 'Insulin is required to maintain albumin expression by inhibiting forkhead box O1 protein', *Journal of Biological Chemistry*, 291(5), pp. 2371–2378. doi: 10.1074/jbc.M115.677351.
- Chevret S, Hughes RAC, Annane D. (2017) 'Plasma exchange for Guillain-Barré syndrome'. *Cochrane Database of Systematic Reviews*, Issue 2. Art. No.: CD001798. DOI: 10.1002/14651858.CD001798.pub3.
- Chiba, A., Kusunoki, S., Shimizu, T. and Kanazawa, I. (1992) 'Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome', *Annals of Neurology*, 31(6), pp. 677–679. doi: 10.1002/ana.410310619.
- Cho, Y. M., Choi, I. S., Bian, R. X., Kim, J. H., Han, J. Y. and Lee, S. G. (2008) 'Serum albumin at admission for prediction of functional outcome in ischaemic stroke patients', *Neurological Sciences*, 29(6), pp. 445–449. doi: 10.1007/s10072-008-1024-0.
- Don, B. R. and Kaysen, G. (2004) 'Serum albumin: Relationship to inflammation and nutrition', *Seminars in Dialysis*, 17(6), pp. 432–437. doi: 10.1111/j.0894-0959.2004.17603.x.
- El-Ghanem, M., Gomez, F., Nasar, A., Souayah, N. (2016) 'IVIg Versus Plasmapheresis Outcomes and Costs in Patients Diagnosed with Guillain-Barre Syndrome (2009-2013). A New York Statewide Planning and Research Cooperation System (SPARCS) Database Report'. *Neurology* Apr, 86 (16 Supplement) P2.273;
- Ethemoglu, O. and Calik, M. (2018) 'Effect of serum inflammatory markers on the prognosis of adult and pediatric patients with guillain-barré syndrome', *Neuropsychiatric Disease and Treatment*, 14, pp. 1255–1260. doi: 10.2147/NDT.S162896.
- Fanali, G., Di Masi, A., Trezza, V., Marino, M., Fasano, M. and Ascenzi, P. (2012) 'Human serum albumin: From bench to bedside', *Molecular Aspects of Medicine*. Elsevier Ltd, 33(3), pp. 209–290. doi: 10.1016/j.mam.2011.12.002.

- Fisher, M. (1956) 'An unusual variant of acute idiopathic polyneuritis', *The New England journal of medicine*, 255(2), pp. 57–65.
- Fokkink, W. J. R., Walgaard, C., Kuitwaard, K., Tio-Gillen, A. P., Van Doorn, P. A. and Jacobs, B. C. (2017) 'Association of albumin levels with outcome in intravenous immunoglobulin-treated guillain-Barré syndrome', *JAMA Neurology*, 74(2), pp. 189–196. doi: 10.1001/jamaneurol.2016.4480.
- Friedman, A. N. and Fadem, S. Z. (2010) 'Reassessment of albumin as a nutritional marker in kidney disease', *Journal of the American Society of Nephrology*, 21(2), pp. 223–230. doi: 10.1681/ASN.2009020213.
- Hughes, R. A. C. (1997) 'Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome', *Lancet*, 349(9047), pp. 225–230. doi: 10.1016/S0140-6736(96)09095-2.
- Hughes, R. A. C., Newsom-Davis, J. M., Perkin, G. D. and Pierce, J. M. (1978) 'Controlled Trial of Prednisolone in Acute Polyneuropathy', *The Lancet*, 312(8093), pp. 750–753. doi: 10.1016/S0140-6736(78)92644-2.
- Hughes, R. A. C., Swan, A. V., Raphaël, J. C., Annane, D., Van Koningsveld, R. and Van Doorn, P. A. (2007) 'Immunotherapy for Guillain-Barré syndrome: A systematic review', *Brain*, 130(9), pp. 2245–2257. doi: 10.1093/brain/awm004.
- Hutson, S. M., Stinson-Fisher, C., Shiman, R. and Jefferson, L. S. (1987) 'Regulation of albumin synthesis by hormones and amino acids in primary cultures of rat hepatocytes', *American Journal of Physiology - Endocrinology and Metabolism*, 252(3). doi: 10.1152/ajpendo.1987.252.3.e291.
- Jacob, S., & Rajabally, Y. A. (2009). 'Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies'. *Current neuropharmacology*, 7(4), 337–342. <https://doi.org/10.2174/157015909790031166>
- Kleyweg RP, van der Meche' FGA, M. J. (1988) 'Guillain-Barre syndrome with high- dose gammaglobulin', *Neurology*, (October), pp. 1639–1642.
- Kratz, F. (2008) 'Albumin as a drug carrier: Design of prodrugs, drug conjugates

- and nanoparticles', *Journal of Controlled Release*. Elsevier B.V., 132(3), pp. 171–183. doi: 10.1016/j.jconrel.2008.05.010.
- Kleyweg RP, van der Mechè FGA, Schmitz PIM. (1991). Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barrè syndrome. *Muscle Nerve*;14:1103-1109.
- Kuwabara, S. and Yuki, N. (2013) 'Axonal Guillain-Barré syndrome: Concepts and controversies', *The Lancet Neurology*. Elsevier Ltd, 12(12), pp. 1180–1188. doi: 10.1016/S1474-4422(13)70215-1.
- LeVine, S. M. (2016) 'Albumin and multiple sclerosis', *BMC Neurology*. BMC Neurology, 16(1), pp. 1–12. doi: 10.1186/s12883-016-0564-9.
- Levitt, D. G. and Levitt, M. D. (2016) 'Human serum albumin homeostasis: A new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements', *International Journal of General Medicine*, 9, pp. 229–255. doi: 10.2147/IJGM.S102819.
- Lukito, V., Mangunatmadja, I., Pudjiadi, A. H. and Puspanjono, T. M. (2016) 'Plasmaferesis Sebagai Terapi Sindrom Guillain-Barre Berat pada Anak', *Sari Pediatri*, 11(6), p. 448. doi: 10.14238/sp11.6.2010.448-55.
- McLeod BC. (2006). 'Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange', *Best Pract Res Clin Haematol.*;19(1):157-67. doi: 10.1016/j.beha.2005.01.004. PMID: 16377548.
- McNurlan, M. A., Sandgren, A., Hunter, K., Essén, P., Garlick, P. J. and Wernerman, J. (1996) 'Protein synthesis rates of skeletal muscle, lymphocytes, and albumin with stress hormone infusion in healthy man', *Metabolism: Clinical and Experimental*, 45(11), pp. 1388–1394. doi: 10.1016/S0026-0495(96)90120-1.
- Nawa, K., Nakamura, T., Kumatori, A., Noda, C. and Ichihara, A. (1986) 'Glucocorticoid-dependent expression of the albumin gene in adult rat hepatocytes', *Journal of Biological Chemistry*, 261(36), pp. 16883–16888.

- Nicholson, J. P., Wolmarans, M. R. and Park, G. R. (2000) 'REVIEW ARTICLE The role of albumin in critical illness', *British Journal of Anaesthesia*, 85(4), pp. 599–610.
- Ozdemir, H. H. (2016) 'Analysis of the albumin level, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio in Guillain-Barré syndrome', *Arquivos de Neuro-Psiquiatria*, 74(9), pp. 718–722. doi: 10.1590/0004-282X20160132.
- Prajapati, K. D., Sharma, S. S. and Roy, N. (2011) 'Current perspectives on potential role of albumin in neuroprotection', *Reviews in the Neurosciences*, 22(3), pp. 355–363. doi: 10.1515/RNS.2011.028.
- Rac, H., Aa, G. and Pa, D. (2016) 'Corticosteroids for Guillain-Barré syndrome (Review)'. doi: 10.1002/14651858.CD001446.pub5.Copyright.
- Rothschild, M. A., Oratz, M. and Schreiber, S. S. (1975) 'Regulation of Albumin Metabolism', *Annual Review of Medicine*, 26(1), pp. 91–104. doi: 10.1146/annurev.me.26.020175.000515.
- Rothschild, M. A., Oratz, M. and Schreiber, S. S. (1988) 'Serum albumin', *Hepatology*, 8(2), pp. 385–401. doi: 10.1002/hep.1840080234.
- Schnitzer, J. E. and Bravo, J. (1993) 'High affinity binding, endocytosis, and degradation of conformationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors', *Journal of Biological Chemistry*, 268(10), pp. 7562–7570.
- Sejvar, J. J., Baughman, A. L., Wise, M. and Morgan, O. W. (2011) 'Population incidence of Guillain-Barré syndrome: A systematic review and meta-analysis', *Neuroepidemiology*, 36(2), pp. 123–133. doi: 10.1159/000324710.
- Su, Z., Chen, Z., Xiang, Y., Wang, B., Huang, Y., Yang, D., Li, X., Weng, Y., Lin, X., Chen, G., Liu, W., Zhao, C., Wang, Q., Li, S., Chen, Y., Chen, Y., Quan, W., Tong, Q., Wu, S., et al. (2017) 'Low serum levels of uric acid and albumin in patients with Guillain – Barre syndrome', 15(January), pp. 1–5.

- Tunç, A. (2019) 'Early predictors of functional disability in Guillain–Barré Syndrome', *Acta Neurologica Belgica*. Springer International Publishing, 119(4), pp. 555–559. doi: 10.1007/s13760-019-01133-3.
- Van Den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B. C. and Van Doorn, P. A. (2014) 'Guillain-Barré syndrome: Pathogenesis, diagnosis, treatment and prognosis', *Nature Reviews Neurology*. Nature Publishing Group, 10(8), pp. 469–482. doi: 10.1038/nrneuro.2014.121.
- van der Meche' FGA, S. P. (1992) 'A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre' syndrome', *The New England Journal of Medicine*, 326(10), pp. 653–657.
- Wakerley, B. R. and Yuki, N. (2013) 'Infectious and noninfectious triggers in Guillain-Barré syndrome', *Expert Review of Clinical Immunology*, 9(7), pp. 627–639. doi: 10.1586/1744666X.2013.811119.
- Weng, Y. Y., Yang, D. H., Qian, M. Z., Wei, M. M., Yin, F., Li, J., Li, X., Chen, Y., Ding, Z. N., He, Y. B. and Zhang, X. (2016) 'Low serum albumin concentrations are associated with disease severity in patients with myasthenia gravis', *Medicine (United States)*, 95(39), pp. 1–5. doi: 10.1097/MD.0000000000005000.
- Willison, H. J. and Yuki, N. (2002) 'Peripheral neuropathies and anti-glycolipid antibodies', *Brain*, 125(12), pp. 2591–2625. doi: 10.1093/brain/awf272.
- Willison, H. J., Jacobs, B. C. and van Doorn, P. A. (2016) 'Guillain-Barré syndrome', *The Lancet*, 388(10045), pp. 717–727. doi: 10.1016/S0140-6736(16)00339-1.
- Yamaguchi, M., Igarashi, A., Misawa, H. and Tsurusaki, Y. (2003) 'Enhancement of albumin expression in bone tissues with healing rat fractures', *Journal of Cellular Biochemistry*, 89(2), pp. 356–363. doi: 10.1002/jcb.10510.
- Yuki, N., Ho, T. W., Tagawa, Y., Koga, M., Li, C. Y., Hirata, K. and Griffin, J. W. (1999) 'Autoantibodies to GM1b and GalNAc-GD1a: Relationship to *Campylobacter jejuni* infection and acute motor axonal neuropathy in China', *Journal of the Neurological Sciences*, 164(2), pp. 134–138. doi: 10.1016/S0022-510X(99)00056-8.



Yuki, N. and Hartung, H. (2012) ‘Guillain–Barré Syndrome’, The New England Journal of Medicine, 366, pp. 1653–1666.

Zhang, Y., Zhao, Y. and Wang, Y., 2018. Prognostic factors of Guillain-Barré syndrome: a 111-case retrospective review. Chinese Neurosurgical Journal, 4(1).